ArticleBritish journal of cancer2014

Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy.

A Sathe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.